ArticleCancer2020
Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
Article in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 47 citations in OpenAlex.
- Effectiveness of mHealth intervention for trismus exercise in patients with head and neck cancer undergoing proton and heavy ion therapy: a randomized control trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Trial
- A new perspective on radiotherapy in the comprehensive treatment of cancer.Precision radiation oncology · 2026Review
- De-Escalation Strategies in Nasopharyngeal Carcinoma.Current oncology reports · 2026Review
- Review
- Compassionate boron neutron capture therapy for locally recurrent nasopharyngeal cancer: A retrospective study.Journal of the Chinese Medical Association : JCMA · 2026Article
- Normal tissue complication probability model of temporal lobe injury following re-irradiation of CIRT for local recurrent nasopharyngeal carcinoma.Frontiers in oncology · 2026Article
- Beyond local control: radiotherapy-immunotherapy combinations fromFrontiers in genetics · 2026Review
- Endoscopic surgery and temporalis muscle flap reconstruction for skull base osteoradionecrosis after radiotherapy.Frontiers in oncology · 2026Article
- Outcomes and recurrence pattern analysis of intensity modulated chemoradiotherapy in nasopharyngeal cancer: a retrospective study from Heidelberg University Hospital.Radiation oncology (London, England) · 2025Article
- Upright positioning enhances beam angle optimization and organ sparing in head and neck carbon-ion radiotherapy with fixed-beam systems.Radiation oncology (London, England) · 2025Article
- Imaging of Carotid Blowout Syndrome in a Patient with Nasopharyngeal Carcinoma After Radiation Therapy.Current medical imaging · 2025Article
- Inhibition of DDR1 potentiates carbon ion radiotherapy by promoting ferroptosis and immunogenic death in head and neck squamous cell carcinoma.Journal of translational medicine · 2025Article
- Autophagy-dependent sensitization effects of PARP inhibitors on recurrent nasopharyngeal carcinoma treated with carbon ion and photon irradiation.Acta biochimica et biophysica Sinica · 2025Article
- Carbon Ion Radiotherapy in the Head and Neck Cancers Treatment and its Potential Role in Personalized Treatment Approach- A Review of the Current Knowledge.Current oncology reports · 2025Review
- Mechanism of skull base osteoradionecrosis explored through laboratory assessment with propensity score-matched analysis.Scientific reports · 2025Article
- Article
- Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities.The Lancet. Oncology · 2024Review
- Precision radiotherapy for nasopharyngeal carcinoma.Precision radiation oncology · 2024Review
- A protocol for a randomized trial evaluating the role of carbon-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma.Cancer medicine · 2024Article
- Advances in the field of developing biomarkers for re-irradiation: a how-to guide to small, powerful data sets and artificial intelligence.Expert review of precision medicine and drug development · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundReirradiation for locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) after high-dose radiotherapy (RT) is challenging and usually is associated with poor survival and severe toxicities. Because of its physical and biological advantages over photon-beam RT, carbon-ion RT (CIRT) could be a potential treatment option for patients with LR-NPC.
methodsPatients with LR-NPC who underwent salvage therapy using CIRT at the Shanghai Proton and Heavy Ion Center between May 2015 and June 2019 were analyzed. CIRT doses were 50 to 69 gray equivalent (GyE) (2.0-3.0 GyE per fraction). Overall survival (OS), local control, regional control, distant control, and acute and late toxicities were analyzed. Univariable and multivariable analyses of OS and local control were performed using the Cox regression model.
resultsAmong the 206 patients included, 139 patients (67.5%) had recurrent American Joint Committee on Cancer stage III or stage IV disease. With a median follow-up of 22.8 months, the 2-year OS, local control, regional control, and distant control rates were 83.7%, 58.0%, 87.3%, and 94.7%, respectively. Multivariable analysis revealed that older age (P = .017) was predictive of worse OS, whereas a larger tumor volume (P = .049) and a lower biological equivalent dose (P = .029) were associated with inferior local control. No patient developed an acute toxicity of ≥grade 3 during CIRT. Severe (≥grade 3) late toxicities included temporal lobe necrosis (0.97%), cranial neuropathy (0.49%), hearing loss (1.46%), xerostomia (0.49%), and mucosal necrosis (16.02%) (toxicities were graded using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer criteria).
conclusionsSalvage treatment using CIRT is efficacious for patients with LR-NPC and its toxicities are acceptable. CIRT may improve the survival and toxicity profiles substantially for patients with LR-NPC compared with the reported results after photon-based intensity-modulated RT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.